# Human Bioequivalence Test (Fasting & Postprandial) of Iloperidone Tablets

> **NCT03420534** · PHASE1 · UNKNOWN · sponsor: **CSPC ZhongQi Pharmaceutical Technology Co., Ltd.** · enrollment: 36 (actual)

## Conditions studied

- Bioequivalence

## Interventions

- **DRUG:** Iloperidone 1 MG
- **DRUG:** Placebo
- **DIETARY_SUPPLEMENT:** fasting
- **DIETARY_SUPPLEMENT:** postprandial

## Key facts

- **NCT ID:** NCT03420534
- **Lead sponsor:** CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-11-17
- **Primary completion:** 2017-12-14
- **Final completion:** 2018-03-14
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2018-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03420534

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03420534, "Human Bioequivalence Test (Fasting & Postprandial) of Iloperidone Tablets". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT03420534. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*